U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs

The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.